Welcome to our dedicated page for Ainos SEC filings (Ticker: AIMDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ainos's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ainos's regulatory disclosures and financial reporting.
ASE Test, Inc., a 10% owner of Ainos, Inc., reported an open-market purchase of 6% Convertible Notes due 2027. The transaction covers 5,994 units of the note, each currently convertible into Ainos common stock at a $22.50 per share conversion price. Following this transaction, ASE Test, Inc. holds 105,868 units of the convertible note. The notes bear 6% compounded interest and have a maturity date extended to March 12, 2027 under an amended agreement.
ASE Technology Holding and subsidiary ASE Test, Inc. report beneficial ownership of 667,085 shares of Ainos, Inc. common stock, representing 8.4% of the class. This stake combines 11,777 shares held directly with shares issuable from a $2,000,000 2023 convertible note, a $9,000,000 2024 convertible note, and a warrant for 100,000 shares, all reflecting a one-for-five reverse stock split completed in June 2025. The notes bear 6% compound interest and are convertible primarily at $22.50 per share. ASE Test Taiwan has also granted Ainos KY broad voting discretion over its Ainos shares and agreed to annual transfer limits, underscoring a long-term, structured investment relationship.
Ainos, Inc. reported full-year 2025 results and highlighted early commercialization of its AI Nose platform. Revenue reached $124,157, up about 499% from 2024, with gross margin turning positive at roughly 82.9% after a prior-year gross loss.
Despite this top-line growth, Ainos posted a net loss of about $14.8 million, similar to 2024, as operating expenses were roughly $14.1 million. Cash and cash equivalents fell to about $417,353 versus $3.9 million a year earlier. After year-end the company raised NTD 90 million (approximately $2.82 million) to support operations and AI Nose deployment.
For 2026, Ainos is rolling out AI Nose in semiconductor environments, including around 200 systems for front-end wafer fabs and about 1,400 systems under a three-year $2.1 million deployment in semiconductor packaging and testing, with a potential roadmap to scale substantially if validations succeed.
Taiwan Carbon Nano Technology Corporation (TCNT) updated its ownership and voting arrangements in Ainos, Inc. TCNT now beneficially owns 989,925 shares of Ainos common stock, representing 13.62% of the outstanding shares, after recent sales including 46,000 shares sold on January 28, 2026.
The filing explains that TCNT originally received Ainos shares in August 2024 under a license agreement, in exchange for granting an exclusive, irrevocable, and perpetual license to certain gas sensor and medical device patents. Ainos later implemented a one‑for‑five reverse stock split and TCNT has been gradually selling shares.
On January 1, 2026, TCNT entered into a voting agreement with Ainos Inc., a Cayman Islands corporation, covering the Ainos shares held by TCNT. Under this agreement, TCNT agreed to vote all of its Ainos voting stock as determined by Ainos KY in its sole discretion, effectively transferring voting control while retaining economic ownership.
Ainos, Inc. filed Amendment No. 14 to its Schedule 13D updating its ownership in Ainos, Inc., a Texas corporation. The filing reports beneficial ownership of 491,263 shares of common stock, representing 6.76% of the outstanding class. Ainos Inc. (Cayman Islands) also holds sole voting power over 3,536,073 shares, including shares subject to voting agreements with several shareholders and ASE Test, Inc., though these 3,044,810 voting-agreement shares are excluded from its reported beneficial ownership. The amendment notes that Taiwan Carbon Nano Technology Corporation sold 46,000 shares subject to the 2026 Voting Agreement and reiterates that the position is held for investment purposes, while leaving open the possibility of future discussions about strategic transactions.
Taiwan Carbon Nano Technology Corp, a more than 10% owner of Ainos, Inc., reported selling 46,000 shares of Ainos common stock on January 28, 2026 at an average price of $2.1697 per share for general operating purposes.
After this transaction, the reporting shareholder directly owned 989,925 Ainos common shares.
ScentAI Inc., a wholly owned subsidiary of Ainos, Inc., filed a Schedule 13D reporting beneficial ownership of 1,160,000 shares of Ainos common stock, representing 16.50% of the outstanding class. These shares have no voting power for so long as they are held by the wholly owned subsidiary.
ScentAI acquired the 1,160,000 Ainos shares on December 30, 2025 in exchange for 116,000,000 shares of ScentAI common stock. The filing states the stake was acquired for investment and general corporate purposes and notes that ScentAI currently has no specific plans for corporate actions involving Ainos, though it may review and change its intentions over time.
Ainos, Inc. filed an 8-K to report an update to its at-the-market stock offering program with H.C. Wainwright & Co., LLC as placement agent. The company previously established an agreement on May 31, 2024 to sell common stock with an aggregate offering price of up to $1,353,197, which was increased by a July 11, 2024 prospectus supplement to $1,840,350. Ainos has already sold common shares with an aggregate sales price of approximately $1,840,337 under this program. On September 5, 2025, Ainos filed a new prospectus supplement for an additional $874,496 of common stock under the same at-the-market agreement.
Ainos, Inc. is updating its at-the-market equity program to offer and sell up to $874,496 of common stock through H.C. Wainwright & Co. as sales agent. This supplements its existing Sales Agreement and reflects the updated capacity the company may use from time to time under its shelf registration. The filing notes that Ainos has already sold $1,840,337 of securities under the Sales Agreement and General Instruction I.B.6 of Form S-3 during the prior 12-month period. As of September 5, 2025, public float was about $8,144,499, based on 4,759,021 shares outstanding at a price of $4.11 per share, which constrains primary offerings to no more than one-third of that float in any 12-month period while float remains below $75 million.
Ainos, Inc. reported that it furnished its financial results for the quarter ended June 30, 2025 via a Current Report on Form 8-K dated August 13, 2025. The filing states a press release announcing those results is furnished as Exhibit 99.1 and that a Cover Page Interactive Data File is included as Exhibit 104. The report notes these materials are being furnished and are not deemed "filed" for purposes of Section 18 of the Exchange Act.
The 8-K identifies the company as a Texas corporation with principal offices in San Diego and lists its common stock (AIMD) and warrants (AIMDW) as Nasdaq-listed securities. The report is signed by Chun-Hsien Tsai, Chief Executive Officer. No financial amounts or results are included directly in the text of this Form 8-K.